Patients' knowledge about renal secondary effects of anti-tumoral drugs and renal protection measures.
Anti-tumoral drugs
Onco-nephrology
Patient education
Patient empowerment
Renal toxicity
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
31
01
2024
accepted:
23
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Onco-nephrology is an emerging subspecialty aiming to better understand and prevent renal events in cancer patients. We assessed patients' knowledge about (1) oncological/hematological treatments induced renal toxicity and (2) kidney protective measures. Adult patients receiving systemic anti-tumor treatments in multiple day hospital units in France answered a self-administered questionnaire about their knowledge and expectations related to treatment-associated renal toxicity. In total, 621 questionnaires were collected in 8 units from November 2021 to January 2022. Among respondents, 84.5% were treated for a solid tumor. Overall, 34.3% (n = 208) patients reported they had some knowledge about potential renal adverse events related to their anticancer treatment, and 38.5% (n = 234) about kidney protection measures. Their referring oncologist or hematologist represented the commonest source of knowledge (67.8%). Sufficient hydration was cited as a kidney protection measure by 93.2% (n = 218) of patients declaring some knowledge about renal toxicity; prevention of nausea/vomiting by 52.6% (n = 123). Consumption of still and alkaline water was chosen by respectively 64.4% (n = 400) and 16.8% (n = 104) of participants to correct dehydration. A majority of patients expressed strong interest for receiving more information about renal toxicity and prevention: median Likert scale score was 10/10 (Q1-Q3, 5-10), with online resources mentioned as the most desired source of information. One-third of patients declared they had some knowledge about potential renal toxicity of their oncologic treatment and the ways to prevent them, especially regarding hydration. However, a majority expressed interest for dedicated information, which conducted to the elaboration of free online educational sheets for patients.
Identifiants
pubmed: 39482406
doi: 10.1007/s00520-024-08956-8
pii: 10.1007/s00520-024-08956-8
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
763Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer 110:1376–1384. https://doi.org/10.1002/cncr.22904
doi: 10.1002/cncr.22904
pubmed: 17634949
Kitchlu A, McArthur E, Amir E et al (2019) Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst 111:727–736. https://doi.org/10.1093/jnci/djy167
doi: 10.1093/jnci/djy167
pubmed: 30423160
Rosner MH, Perazella MA (2017) Acute kidney injury in patients with cancer. N Engl J Med 376:1770–1781. https://doi.org/10.1056/NEJMra1613984
doi: 10.1056/NEJMra1613984
pubmed: 28467867
Malyszko J, Kozlowska K, Kozlowski L, Malyszko J (2017) Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 32:924–936. https://doi.org/10.1093/ndt/gfw338
doi: 10.1093/ndt/gfw338
Overall readmissions and readmissions related to dehydration after creation of an ileostomy: a systematic review and meta-analysis - PubMed. https://pubmed.ncbi.nlm.nih.gov/35192122/ . Accessed 20 Mar 2023
García-Carro C, Draibe J, Soler MJ (2023) Onconephrology: update in anticancer drug-related nephrotoxicity. Nephron 147:65–77. https://doi.org/10.1159/000525029
doi: 10.1159/000525029
pubmed: 35717937
Nephrotoxicity in cancer treatment: an overview - PubMed. https://pubmed.ncbi.nlm.nih.gov/32355641/ . Accessed 6 Sep 2024
Lameire NH, Flombaum CD, Moreau D, Ronco C (2005) Acute renal failure in cancer patients. Ann Med 37:13–25. https://doi.org/10.1080/07853890510007205
doi: 10.1080/07853890510007205
pubmed: 15902843
Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol CJASN 7:1713–1721. https://doi.org/10.2215/CJN.02780312
doi: 10.2215/CJN.02780312
pubmed: 22879440
Gupta S, Portales-Castillo I, Daher A, Kitchlu A (2021) Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis 28:402-414.e1. https://doi.org/10.1053/j.ackd.2021.08.001
doi: 10.1053/j.ackd.2021.08.001
pubmed: 35190107
Ishitsuka R, Miyazaki J, Ichioka D et al (2017) Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clin Exp Nephrol 21:732–740. https://doi.org/10.1007/s10157-016-1327-z
doi: 10.1007/s10157-016-1327-z
pubmed: 27565169
Launay-Vacher V (2010) Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 30:548–556. https://doi.org/10.1016/j.semnephrol.2010.09.003
doi: 10.1016/j.semnephrol.2010.09.003
pubmed: 21146120
Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609–619. https://doi.org/10.1634/theoncologist.2016-0319
doi: 10.1634/theoncologist.2016-0319
pubmed: 28438887
pmcid: 5423518
Delaye M, Try M, Campedel L et al (2022) Development and organization of onco-nephrology in France, comment on “The path toward the creation of the American Society of Onco-Nephrology (ASON).” J Onco-Nephrol 6:239936932211064. https://doi.org/10.1177/23993693221106490
doi: 10.1177/23993693221106490
Olié V, Cheddani L, Stengel B et al (2021) Prevalence of chronic kidney disease in France, Esteban study 2014–2016. Nephrol Ther 17:526–531. https://doi.org/10.1016/j.nephro.2021.05.006
doi: 10.1016/j.nephro.2021.05.006
pubmed: 34629319
Izzedine H, Mateus C, Boutros C et al (2017) Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 32:936–942. https://doi.org/10.1093/ndt/gfw382
doi: 10.1093/ndt/gfw382
pubmed: 28025384
Launay-Vacher V, Aapro M, De Castro G et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677–1684. https://doi.org/10.1093/annonc/mdv136
doi: 10.1093/annonc/mdv136
pubmed: 25735315
Rashidi A, Jhaveri KD, Workeneh BT, Gupta S (2022) The path toward the creation of the American Society of Onco-Nephrology (ASON). J Onco-Nephrol 6:3–5. https://doi.org/10.1177/23993693221079647
doi: 10.1177/23993693221079647
(2021) ASSOGRIFON. https://assogrifon.webnode.fr/ . Accessed 12 Mar 2023
Fofi C, Festuccia F (2021) Onconephrology: a new challenge for the nephrologist. Contrib Nephrol 199:91–105. https://doi.org/10.1159/000517695
doi: 10.1159/000517695
pubmed: 34375977
Cosmai L, Porta C, Perazella MA et al (2018) Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 33:1503–1510. https://doi.org/10.1093/ndt/gfy188
doi: 10.1093/ndt/gfy188
Delaye M, Try M, Rousseau A et al (2022) Onco-nephrology: physicians’ expectations about a new subspecialty. J Cancer Educ Off J Am Assoc Cancer Educ. https://doi.org/10.1007/s13187-022-02201-8
doi: 10.1007/s13187-022-02201-8